They suggested that patients with CML with a3 transcripts show a low proportion of circulating immature cells, mild or no splenomegaly, slow progression, resistance to IFN-α, and a good response to imatinib mesylate.[17] In 2018, Qin et al[18] screened 83 patients with rare BCR::ABL transcripts from 4750 CML patients, including 11 cases of e14a3 and 6 cases of e13a3. Here, ABL1 is linked to Splenomegaly.